loteprednol etabonate

FDA Drug Profile — Inveltys, Loteprednol Etabonate, Alrex, LOTEMAX, Lotemax SM

loteprednol etabonate is listed in the FDA National Drug Code directory with 23 NDC codes, marketed under brand names including Inveltys, Loteprednol Etabonate, Alrex. Available dosage forms: suspension, suspension/ drops, powder, gel, ointment.

Drug Details

Generic Name
loteprednol etabonate
Brand Names
Inveltys, Loteprednol Etabonate, Alrex, LOTEMAX, Lotemax SM, LOTEPREDNOL ETABONATE, Lotemax, Eysuvis, loteprednol etabonate
Application Number
NDA210565
Sponsor
ALCON LABORATORIES, INC.
NDC Codes
23
Dosage Forms
SUSPENSION, SUSPENSION/ DROPS, POWDER, GEL, OINTMENT
Routes
TOPICAL, OPHTHALMIC
Active Ingredients
LOTEPREDNOL ETABONATE

Indications and Usage

INDICATIONS AND USAGE Loteprednol etabonate ophthalmic suspension is indicated for the treatment of steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation. Loteprednol etabonate is less effective than prednisolone acetate 1% in two 28-day controlled clinical studies in acute anterior uveitis, where 72% of patients treated with loteprednol etabonate experienced resolution of anterior chamber cells, compared to 87% of patients treated with prednisolone acetate 1%. The incidence of patients with clinically significant increases in IOP (≥10 mmHg) was 1% with loteprednol etabonate and 6% with prednisolone acetate 1%. Loteprednol etabonate should not be used in patients who require a more potent corticosteroid for this indication. Loteprednol etabonate ophthalmic suspension is also indicated for the treatment of post-operative inflammation following ocular surgery.

Warnings

WARNINGS Prolonged use of corticosteroids may result in glaucoma with damage to the optic nerve, defects in visual acuity and fields of vision, and in posterior subcapsular cataract formation. Steroids should be used with caution in the presence of glaucoma. Prolonged use of corticosteroids may suppress the host response and thus increase the hazard of secondary ocular infections. In those diseases causing thinning of the cornea or sclera, perforations have been known to occur with the use of topical steroids. In acute purulent conditions of the eye, steroids may mask infection or enhance existing infection. Use of ocular steroids may prolong the course and may exacerbate the severity of many viral infections of the eye (including herpes simplex). Employment of a corticosteroid medication in the treatment of patients with a history of herpes simplex requires great caution. The use of steroids after cataract surgery may delay healing and increase the incidence of bleb formation.